Drug Type Small molecule drug |
Synonyms Ondansetron/rizatriptan transmucosal, Rizatriptan/ondansetron |
Mechanism 5-HT1B receptor agonists(Serotonin 1b (5-HT1b) receptor agonists), 5-HT1D receptor agonists(Serotonin 1d (5-HT1d) receptor agonists), 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H22ClN3O2 |
InChIKeyWRZJOBREMUDSSV-UHFFFAOYSA-N |
CAS Registry103639-04-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | Phase 1 | US | - | |
Nausea | Phase 1 | US | - |